| Technology Overview　AC-03 | ||
| Technology | Novel Furoquinoline Compounds with Anti-mitotic Properties | |
| Mechanism | Induce apoptosis by directly binding to b-tubulin and inhibit micro-tubulin polymerization | |
| Indication | Small molecule agents for cancer treatment | |
| Efficacy | General pharmacology | - Ligand binding assay: 5-HT2B receptor - Xenograft model: A549, HeLa, HL-60 |
| Safety pharmacology | - MTD assay | |
| Preliminary Pharmacokinetics Studies | ||
| Development Stage | Pre-clinical stage (Conducting Comprehensive PK & Toxicology studies) |
|
| Intellectual Property | U.S Patent #6,750,223 B2 (03' issued), #6,656,949 (04' issued), TW Patent #248,937 (06. issued) | |
| Collaboration Opportunity | Technology licensing, Co-development, Research collaboration | |
|